Safety and Efficacy of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea
| Status: | Completed |
|---|---|
| Conditions: | Cosmetic, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/11/2015 |
| Start Date: | June 2014 |
| End Date: | June 2015 |
| Contact: | Allergan Inc. |
| Email: | clinicaltrials@allergan.com |
This study will evaluate the safety and efficacy of AGN-199201 once daily compared to
vehicle for the treatment of persistent moderate to severe facial erythema associated with
rosacea.
vehicle for the treatment of persistent moderate to severe facial erythema associated with
rosacea.
Inclusion Criteria:
-Moderate to severe persistent facial erythema associated with rosacea.
Exclusion Criteria:
- Greater than 3 inflammatory lesions on the face
- Current treatment with monoamine oxidase (MAO) inhibitors
- Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or
Sjogren's syndrome.
We found this trial at
1
site
Click here to add this to my saved trials
